Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Reprod Biol Endocrinol. 2005 Nov 9;3:62.

Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.

Author information

  • 1William Beaumont Hospital, In Vitro Fertility Clinic, Royal Oak, Michigan, USA. wkeye@beaumont.edu

Abstract

BACKGROUND:

The safety and tolerability of a new highly purified, urine-derived human menopausal gonadotropin (hMG) preparation [Menopur] was compared with a currently available hMG [Repronex] in women undergoing in vitro fertilization (IVF).

METHODS:

This was a randomized, open-label, parallel-group, multicenter study conducted in subjects undergoing IVF. Women (N = 125), 18-39 years of age, underwent pituitary down-regulation with leuprolide acetate beginning 7 days prior to onset of menses and continuing up to the day before hCG administration. Subjects were randomized to receive subcutaneous (SC) Menopur (n = 61) or Repronex SC (n = 64) for a maximum of 12 days. All adverse events (AEs) were recorded and subject self-assessments of injection site reactions were recorded in a daily diary.

RESULTS:

Significantly fewer subjects in the Menopur group reported injection site reactions (P < 0.001) compared to the Repronex group. Overall, there was no statistically significant difference in the incidence of AEs between the two treatment groups.

CONCLUSION:

Menopur SC offers a greater safety and tolerability profile compared to Repronex SC.

PMID:
16280073
[PubMed - indexed for MEDLINE]
PMCID:
PMC1309620
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk